The Vanguard Group, Inc. has recently announced that it has increased stake in AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) by 22.55%. After grabbing 0.23 million shares, the institutional investor is now in possession of 41600.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 3.03% having worth around $0.54 million. Moreover, BlackRock Fund Advisors increased its share by 1000.0 to have a control over 97175.0 shares. And Geode Capital Management LLC raised its holdings to 4224.0 shares by acquiring 58104.0 shares or 0.78% of the stake.
AcelRx Pharmaceuticals Inc. (ACRX) concluded trading on 01/12/23 at a closing price of $2.50, with 0.33 million shares of worth about $0.83 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -48.43% during that period and on Thursday the price saw a gain of about 10.13%. Currently the company’s common shares owned by public are about 7.38M shares, out of which, 7.36M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 2 analysts are covering the ACRX stock and their offered price forecasts bring an average price target of $80.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $80.00 and could fall to a lowest price of $80.00. The stock’s current price level is 96.88% above of average price target set by the analysts, while a rise to estimated low would result in gain of 96.88% for the stock. However, touching the estimated high of $80.00 would mean a gain of 96.88% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 24 times over the past 12 months. They bought 882,400 shares in 12 of the transactions. In 12 selling transactions, insiders dumped 141,966 shares.
Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu are the top 3 mutual funds which are holding stakes in AcelRx Pharmaceuticals Inc. Vanguard Total Stock Market Index is currently holding 0.11 million shares of worth totaling $0.27 million. The company recently came buying 0.0 shares which brought its stake up to 1.52% of the company’s outstanding shares. Fidelity Extended Market Index Fu, after buying 30795.0 shares, have now control over 0.41% of the stake in the company. It holds 0.0 shares of worth $73600.0.
AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) started trading at $2.29, above $0.02 from concluding price of the previous day. However, the stock later moved at a day high price of 2.6100, or with a gain of 10.13%. Stock saw a price change of 9.65% in past 5 days and over the past one month there was a price change of 11.61%. Year-to-date (YTD), ACRX shares are showing a performance of 10.62% which decreased to -77.97% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.76 but also hit the highest price of $11.60 during that period. The average intraday trading volume for AcelRx Pharmaceuticals Inc. shares is 157.87K. The stock is currently trading 12.61% above its 20-day simple moving average (SMA20), while that difference is up 12.47% for SMA50 and it goes to -40.43% lower than SMA200.
The Vanguard Group, Inc. acquired 0.23 million shares of AcelRx Pharmaceuticals Inc. having value of about $0.54 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 41600.0 shares in the company valued at close to $104000.0, or have control over 22.55% stake in the company. AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) currently have 7.38M outstanding shares and institutions hold larger chunk of about 12.40% of that. Holding of mutual funds in the company is about 4.39% while other institutional holders and individual stake holders have control over 7.92% and — of the stake respectively.
The stock has a current market capitalization of $19.50M and its 3Y-monthly beta is at 0.26. PE ratio of stock for trailing 12 months is 0.40, while it has posted earnings per share of $6.21 in the same period. It has Quick Ratio of 1.50 while making debt-to-equity ratio of 0.29. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ACRX, volatility over the week remained 9.99% while standing at 11.97% over the month.
Analysts are in expectations that AcelRx Pharmaceuticals Inc. (ACRX) stock would likely to be making an EPS of -$1.2 in the current quarter, while forecast for next quarter EPS is -$0.6 and it is -$2.9 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.2 which is -$1.2 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$1.4 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 38.20% while it is estimated to decrease by -142.20% in next year.
Analysts at 2 brokerage firms have issued recommendations for the AcelRx Pharmaceuticals Inc. (ACRX)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.50. Out of those 2 Wall Street analysts, 1 recommended a “Buy” rating, while 1 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Coverage by Credit Suisse stated AcelRx Pharmaceuticals Inc. (ACRX) stock as a Neutral in their note to investors on November 11, 2019, suggesting a price target of $2 for the stock. Stock get a Buy rating from B. Riley FBR on April 24, 2019.